Longitudinal follow‐up and performance validation of an mRNA‐based urine test (Xpert ^® Bladder Cancer Monitor ) for surveillance in patients with non‐muscle‐invasive bladder cancer

Abstract

The Xpert test has a high sensitivity for detecting the recurrence of cancer and a high NPV for excluding HG cancer. In addition, the data suggest that patients with a positive Xpert assay in the setting of negative cystoscopy are at high risk for recurrence and need close surveillance.